CVRx, Inc.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 21, 2026, CVRx, Inc. (the “Company”) announced that its Board of Directors (the “Board”) appointed John Landry as Chief Financial Officer (“CFO”). Mr. Landry succeeds Jared Oasheim who, as previously disclosed on June 8, 2026, gave notice of his intention to resign as CFO after his successor commences in the role. Mr. Landry’s employment will commence on October 12, 2026 to facilitate a smooth transition before assuming the responsibilities of CFO on the day after the Company files its Form 10-Q for its quarter ending September 30, 2026. A copy of the press release announcing Mr. Landry’s appointment is filed as Exhibit 99.1 hereto. Mr. Landry, age 54, currently serves as Chief Financial Officer of Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat obstructive sleep apnea, a position he has held since November 2024. Mr. Landry previously served as Senior Vice President, Chief Financial Officer, and Treasurer of Vapotherm Inc., a developer and manufacturer of advanced respiratory technology, from July 2020 to October 2024, prior to which he served as Vice President, Chief Financial Officer, Secretary and Treasurer from August 2012 to July 2020. Prior to Vapotherm, Mr. Landry served as Director of International Marketing at Medtronic, Inc. from 2011 to 2012 following its acquisition in August 2011 of Salient Surgical Technologies, Inc., where Mr. Landry held positions of increasing responsibility from 2004 to 2011. Prior to this, Mr. Landry held various financial leadership roles at Bottomline Technologies, Hussey Seating Company, and Coopers & Lybrand LLP. Mr. Landry currently serves on the board of directors of Liberate Medical, Inc. Mr. Landry received a B.S. in Accountancy from Bentley College. He is a certified public accountant (inactive). The Compensation Committee of the Board approved the following compensation for Mr. Landry: (i) an initial annual base salary of $500,000, (ii) a target cash incentive award of 50% of base salary (which will be pro-rated for fiscal 2026), (iii) initial equity awards consisting 75% of stock options and 25% of restricted stock units (“RSUs”) that together represent 0.80% of the base total common shares outstanding as of the date his employment commences, applying a 1.5:1 multiple of options to RSUs, which will have terms consistent with the Company’s current forms of equity awards and will be granted under the Nasdaq inducement grant exemption, (iv) payment of his forfeited pro-rated bonus from his current employer that is subject to repayment if Mr. Landry resigns or is terminated for cause prior to the first anniversary of his hire date, and (v) reimbursement of travel expenses from his residence. Mr. Landry will receive the Company’s standard form of severance agreement for executive officers. The foregoing description of the compensation arrangements is qualified in its entirety by reference to the offer letter, which is filed as Exhibit 10.1 to this Current Report on Form 8-K.